To test the effectiveness of repeat dosing, we sprayed two doses (1013 vg each) of AAV1Δ27-264-CFTR into airways of four rhesus monkeys at 0 and 30 days, followed by a single dose of 1013 vg of AAV1GFP on day 60. Monkeys were sacrificed on day 90. No adverse events occurred, indicating that AAV1 vectors are safe. An elevated anti-AAV1 neutralizing titer was established by the third dose. A positive ELISPOT to the adeno-associated virus (AAV) capsid but not to cystic fibrosis transmembrane conductance regulator (CFTR) occurred after the third dose in three monkeys. AAV1-CFTR and GFP vectors were detectable in all lung sections and in the heart, liver, and spleen. The CFTR protein was higher in treated monkeys than in an untreated monkey. GFP protein was detected in treated lungs. Lung surface and keratin 5-positive basal cells showed higher CFTR staining than in the uninfected monkey and were positive for GFP staining, indicating widespread gene transduction by AAV1CFTR and GFP. AAV1 safely and effectively transduces monkey airway and basal cells. Both the significant numbers of vector genomes and transduction from AAV1CFTR and GFP virus seen in the monkeys 3 months after the first instillation suggest that repeat dosing with AAV1-based vectors is achievable.
Get full access to this article
View all access options for this article.
References
1.
GugginoWB, CebotaruL. Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments. Expert Opin Biol Ther, 2017; 17:1265–1273.
2.
MingozziF, HighKA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet, 2011; 12:341–355.
3.
GruntmanAM, FlotteTR. Progress with recombinant adeno-associated virus vectors for gene therapy of alpha-1 antitrypsin deficiency. Hum Gene Ther Methods, 2015; 26:77–81.
DarrowJJ. Luxturna: FDA documents reveal the value of a costly gene therapy. Drug Discov Today, 2019; 24:949–954.
6.
Spark Therapeutics. FDA Approves Spark Therapeutics' LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy. Press Release: December 19, 2017.
7.
GruntmanAM, BishLT, MuellerC, et al. Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Protoc Microbiol 2013;Chapter 14:Unit 14D.3.
8.
SosnayPR, CastellaniC, CoreyM, et al.Evaluation of the disease liability of CFTR variants. Methods Mol Biol, 2011; 742:355–372.
9.
SosnayPR, SiklosiKR, Van GoorF, et al.Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet, 2013; 45:1160–1167.
10.
FullerCM, BenosDJ. Cftr! Am J Physiol 1992;263:C267–C286.
11.
GoetzD, RenCL. Review of cystic fibrosis. Pediatr Ann, 2019; 48:e154–e161.
LiangJ, BalachandraS, NgoS, et al.Feedback regulation of steady-state epithelial turnover and organ size. Nature, 2017; 548:588–591.
14.
RommensJM, IannuzziMC, KeremB, et al.Identification of the cystic fibrosis gene: chromosome walking and jumping. Science, 1989; 245:1059–1065.
15.
RiordanJR, RommensJM, KeremB, et al.Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 1989; 245:1066–1073.
16.
KeremB, RommensJM, BuchananJA, et al.Identification of the cystic fibrosis gene: genetic analysis. Science, 1989; 245:1073–1080.
FlotteTR, AfioneSA, SolowR, et al.Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem, 1993; 268:3781–3790.
19.
WagnerJA, ReynoldsT, MoranML, et al.Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet, 1998; 351:1702–1703.
20.
WagnerJA, NepomucenoIB, MessnerAH, et al.A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther, 2002; 13:1349–1359.
21.
FlotteTR, ZeitlinPL, ReynoldsTC, et al.Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther, 2003; 14:1079–1088.
22.
BeckSE, JonesLA, ChesnutK, et al.Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol, 1999; 73:9446–9455.
23.
FischerAC, BeckSE, SmithCI, et al.Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Mol Ther, 2003; 8:918–926.
24.
ChmielJF, BergerM, KonstanMW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol, 2002; 23:5–27.
25.
Virella-LowellI, ZusmanB, FoustK, et al.Enhancing rAAV vector expression in the lung. J Gene Med, 2005; 7:842–850.
26.
SirningerJ, MullerC, BraagS, et al.Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther, 2004; 15:832–841.
27.
CarrollTP, MoralesMM, FulmerSB, et al.Alternate translation initiation codons can create functional forms of cystic fibrosis transmembrane conductance regulator. J Biol Chem, 1995; 270:11941–11946.
GaoG, VandenbergheLH, AlviraMR, et al.Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol, 2004; 78:6381–6388.
30.
FlotteTR, FischerAC, GoetzmannJ, et al.Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. Mol Ther, 2010; 18:594–600.
31.
YanZ, Lei-ButtersDC, KeiserNW, et al.Distinct transduction difference between adeno-associated virus type 1 and type 6 vectors in human polarized airway epithelia. Gene Ther, 2013; 20:328–337.
32.
GugginoWB, BensonJ, SeagraveJ, et al.A preclinical study in rhesus macaques for cystic fibrosis to assess gene transfer and transduction by AAV1 and AAV5 with a Dual-Luciferase Reporter System. Hum Gene Ther Clin Dev, 2017; 28:145–156.
33.
CebotaruL, VijN, CiobanuI, et al.Cystic fibrosis transmembrane regulator missing the first four transmembrane segments increases wild type and DeltaF508 processing. J Biol Chem, 2008; 283:21926–21933.
34.
SongS, EmburyJ, LaipisPJ, et al.Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther, 2001; 8:1299–1306.
35.
ZolotukhinS, PotterM, ZolotukhinI, et al.Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods, 2002; 28:158–167.
36.
Lopes-PachecoM, BoinotC, SabirzhanovaI, et al.Combination of correctors rescue deltaF508-CFTR by reducing its association with Hsp40 and Hsp27. J Biol Chem, 2015; 290:25636–25645.
37.
CalcedoR, ChichesterJA, WilsonJM. Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors. Hum Gene Ther Methods, 2018; 29:86–95.
38.
RawlinsEL, HoganBL. Ciliated epithelial cell lifespan in the mouse trachea and lung. Am J Physiol Lung Cell Mol Physiol, 2008; 295:L231–L234.
HongKU, ReynoldsSD, WatkinsS, et al.Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. Am J Pathol, 2004; 164:577–588.
41.
HongKU, ReynoldsSD, WatkinsS, et al.In vivo differentiation potential of tracheal basal cells: evidence for multipotent and unipotent subpopulations. Am J Physiol Lung Cell Mol Physiol, 2004; 286:L643–L649.
42.
FlotteTR. Recent developments in recombinant AAV-mediated gene therapy for lung diseases. Curr Gene Ther, 2005; 5:361–366.
43.
FischerAC, SmithCI, CebotaruL, et al.Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates. Mol Ther, 2007; 15:756–763.
44.
CebotaruL, WoodwardO, CebotaruV, et al.Transcomplementation by a truncation mutant of cystic fibrosis transmembrane conductance regulator (CFTR) enhances DeltaF508 processing through a biomolecular interaction. J Biol Chem, 2013; 288:10505–10512.
45.
MingozziF, HighKA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 2013; 122:23–36.
46.
AfioneSA, WangJ, WalshS, et al.Delayed expression of adeno-associated virus vector DNA. Intervirology, 1999; 42:213–220.
47.
CooneyAL, ThornellIM, SinghBK, et al.A novel AAV-mediated gene delivery system corrects CFTR function in pigs. Am J Respir Cell Mol Biol, 2019; 61:747–754.
48.
BennettWD, ZemanKL, LaubeBL, et al.Homogeneity of aerosol deposition and mucociliary clearance are improved following Ivacaftor treatment in cystic fibrosis. J Aerosol Med Pulm Drug Deliv, 2018; 31:204–211.
49.
LaubeBL, LinksJM, LaFranceND, et al.Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients. Chest, 1989; 95:822–830.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
